KARO BIO AND ALKEM LABORATORIES LTD COLLABORATE TO DEVELOP EPROTIROME
STOCKHOLM, April 26, 2011 – Karo Bio AB (publ) and Alkem Laboratories Ltd have entered into a collaboration and license agreement regarding eprotirome, currently in late-stage clinical testing for dyslipidemia. Karo Bio will grant Alkem rights to commercialize eprotirome in India and certain other countries. Alkem will participate in Karo Bio’s phase III program for eprotirome by conducting a pivotal clinical study on eprotirome in India.Karo Bio has entered into a collaboration and license agreement with the Indian pharmaceutical company Alkem Laboratories Ltd (Alkem). Under the agreement,